Abstract
In a retrospective study, we analyzed the prevalence of subnormal prothrombin time (PT) values in 104 patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with clinicolaboratory features. Reduced PT values (< 70%) were found in 45/104 (43%) patients. The median survival of patients with reduced PT values was significantly shorter than in patients with normal PT (19 vs. 49 months, p = 0.006). Patients with reduced PT had higher leukocyte counts, a higher proportion of circulating blast cells, and lower platelet counts. In patients for whom clinical information was available, there was no difference in the incidence of bleeding complications between patients with or without reduced PT. Our results show a high prevalence of plasmatic coagulation abnormalities in patients with CMML, which were associated with laboratory features of advanced disease. Moreover, subnormal PT values were identified as a new prognostic marker. Reduced PT values do not seem to have a clinical impact regarding bleeding complications.
Keywords: Chronic myelomonocytic leukemia, Prothrombin time, Survival, Coagulation, Prevalence
Abstract
In einer retrospektiven Studie wurde die Prävalenz einer verminderten Prothrombinzeit (PTZ) bei 104 Patienten mit chronischer myelomonozytärer Leukämie (CMML), ihr potenzieller prognostischer Einfluss und ihre potenzielle Korrelation mit klinischen und laborchemischen Parametern untersucht. Eine verminderte PTZ (< 70 %) wurde bei 45/104 (43 %) Patienten gefunden. Das mediane Überleben von Patienten mit verminderten PTZ-Werten war signifikant kürzer als jenes von Patienten mit normalen PTZ-Werten (19 vs. 49 Monate, p = 0,006). Patienten mit verminderten PTZ-Werten wiesen höhere Leukozytenwerte, einen höheren Anteil zirkulierender Blasten und geringere Thrombozytenzahlen auf. Bei Patienten, bei denen klinische Informationen vorlagen, bestand kein Unterschied im Hinblick auf Blutungskomplikationen zwischen beiden Gruppen. Die vorliegenden Ergebnisse zeigen eine hohe Prävalenz plasmatischer Gerinnungsstörungen bei Patienten mit CMML, die mit Laborparametern einer fortgeschrittenen CMML assoziiert waren. Darüber hinaus wurde die PTZ als neuer prognostischer Parameter bei dieser Erkrankung identifiziert. Verminderte PTZ-Werte scheinen jedoch keinen Einfluss auf Blutungskomplikationen zu haben.
Schlüsselwörter: Chronische myelomonozytäre Leukämie, Prothrombinzeit, Überleben, Blutgerinnung, Prävalenz
Introduction
Chronic myelomonocytic leukemia (CMML) is a rare, genotypically and phenotypically heterogenous hematologic malignancy of elderly people, with an intrinsic risk of progression and transformation to secondary acute myeloid leukemia (AML). With regard to the presence of myeloproliferation, CMML was originally subdivided into myeloproliferative disorder (MP-CMML; white blood cell [WBC] count > 13 × 109/L) versus myelodysplastic syndrome (MD-CMML; WBC count ≤ 13 × 109/L MD-CMML) by the FAB criteria [1, 2]. Since CMML is characterized by features of both MDS and MPN, the World Health Organization (WHO) classification of 2002 assigned CMML to the mixed category, MDS/MPN [3]. CMML is further subclassified by the WHO into three groups based on blast equivalents (blasts plus promonocytes) in peripheral blood (PB) and bone marrow (BM) as follows: CMML‑0 if PB < 2% and BM < 5% blast equivalents; CMML‑1 if PB 2–4% or BM 5–9% blast equivalents; and CMML‑2 if PB 5–19% or BM 10–19% blast equivalents, and/or Auer rods are present [4]. CMML patients have a highly variable outcome, suggesting that several factors can determine the course of disease and the causes of death in these patients [5–9]. There are a number of established prognostic parameters that have been incorporated into several prognostic models [10–21]. The clinical significance of disturbed plasmatic coagulation in patients with CMML is poorly investigated. Prothrombin time (PT) is a widely used test of overall clotting function. Using the database of the Austrian Biodatabase for Chronic Myelomonocytic Leukemia (ABCMML), we analyzed 104 CMML patients with available information on PT values and other coagulation parameters [22]. This information from a real-life database could be useful in the management of these patients.
Patients and methods
Patients
Recently, we have shown that the ABCMML may be used as a representative and useful real-life data source for biomedical research [22]. In this database, we retrospectively collected epidemiologic, hematologic, biochemical, clinical, immunophenotypic, cytogenetic, molecular, and biologic data of patients with CMML from different centers. The diagnosis of CMML and leukemic transformation was according to the WHO criteria [2–4]. Clinical and laboratory routine parameters were obtained from patient records. A detailed central manual retrospective chart review was carried out to ensure data quality before analysis of data from institutions. Due to the fact that CMML may be considered as an evolutionary process from clonal hematopoiesis of indeterminate potential (CHIP) to CMML-related AML [23], and the fact that the distinction between mature and immature monocytic cells, which is required to determine the time of transformation into AML, is notoriously difficult due to the lack of reliable immunophenotypic markers, we found it more appropriate not to exclude the few CMML patients with transformation from our analysis [24].
For 104 CMML patients collected between 1.1.1990 and 31.3.2019, information was available regarding PT values. Patients on anticoagulation were not included in this study. This research was approved by the ethics committee of the City of Vienna on 10 June 2015 (ethic code: 15-059-VK).
Statistical analysis
The log-rank test was used to determine whether individual parameters were associated with overall survival (OS). OS was defined as the time from sampling to death (uncensored) or last follow-up (censored). Multivariate Cox regression analysis of overall survival was used to describe the relation between the event incidence, as expressed by the hazard function, and a set of covariates. Dichotomous variables were compared between different groups using the chi-square test. The Mann–Whitney U test was used to compare two unmatched groups when continuous variables were nonnormally distributed. Results were considered significant at p < 0.05. Statistical analyses were performed with the SPSS v. 27 (IBM Corp., Armonk, NY, USA); the reported p-values are two-sided.
Results
Patient characteristics
The baseline characteristics of the 104 patients with CMML are shown in Table 1. In order to make comparisons with other published CMML cohorts possible, the percentages of patients regarding established prognostic parameters are given [17]. As seen in other CMML series, there was a male predominance among study patients and more than half of patients were aged 70 years or older [17]. The proportion of patients with leukocytosis > 13 G/L, anemia < 10 g/dL, thrombocytopenia < 100 G/L, and the presence of blast cells in peripheral blood (PB) was also comparable to other cohorts [17]. Four patients in this cohort have already transformed into CMML-related AML.
Table 1.
Characteristics of chronic myelomonocytic leukemia patients
| Cases (N = 104) | Percent | |
|---|---|---|
|
Age Evaluable = 104 | ||
| < 70 years | 34 | 33 |
| ≥ 70 years | 70 | 67 |
|
Sex Evaluable = 104 | ||
| Male | 75 | 72 |
| Female | 29 | 28 |
|
Leukocytes Evaluable = 104 | ||
| > 13 G/L | 48 | 46 |
| ≤ 13 G/L | 56 | 54 |
|
Hemoglobin Evaluable = 104 | ||
| < 10 g/dL | 29 | 28 |
| ≥ 10 g/dL | 75 | 72 |
|
Platelets Evaluable = 104 | ||
| < 100 G/L | 40 | 38 |
| ≥ 100 G/L | 64 | 62 |
|
Peripheral blood blasts Evaluable = 97 | ||
| Absent | 65 | 67 |
| Present | 32 | 33 |
Prevalence of blood coagulation abnormalities in CMML
Reduced PT values (< 70%) were found in 43/104 (41%) patients. The proportion of patients with hypofibrinogenemia (< 2 g/L) was 10/66 (15%). 2/36 (6%) patients with normal PT values had subnormal fibrinogen levels as compared to 8/30 (27%) patients with decreased PT values. Thus, the proportion of patients with hypofibrinogenemia was significantly higher in patients with reduced PT (p = 0.017).
Correlation of decreased PT values with laboratory phenotype and clinical parameters
As shown in Table 2, CMML patients with decreased PT values significantly clustered with several adverse disease features, such higher leukocyte counts, a higher proportion of circulating blast cells, and lower platelet counts. There was a borderline association with lower hemoglobin levels. In patients for whom clinical information was available, there were 4/26 (15%) patients with bleeding complications in the group with normal PT values as compared to 2/15 (13%) in patients with subnormal PT levels. Thus, there was no difference in the proportion of patients with documented bleeding (p = 0.858).
Table 2.
Laboratory features stratified by the presence or absence of decreased PT value
| All patients (N = 104) |
PT < 70% (n = 43) |
PT ≥ 70% (n = 61) |
P-value | |
|---|---|---|---|---|
|
Age in years; median (range) Evaluable = 104 |
73 (44–92) | 73 (52–90) | 72 (44–92) | 0.776 |
|
Sex (male); n (%) Evaluable = 104 |
74 (71%) | 31 (72%) | 43 (70%) | 0.859 |
|
Leukocytes G/L; median (range) Evaluable = 104 |
12.3 (3.0–238) | 17.8 (4.3–237) | 10.8 (3.0–86.7) | 0.001 |
|
Hemoglobin g/dL; median (range) Evaluable = 104 |
11.4 (4.3–16.5) | 11.2 (4.3–15.3) | 11.8 (6.2–16.5) | 0.424 |
|
Platelets G/L; median (range) Evaluable = 104 |
130 (12–1148) | 77 (12–608) | 150 (23–1148) | 0.000 |
|
PB blasts %; median (range) Evaluable = 94 |
0 (0–94) | 0 (0–94) | 0 (0–18) | 0.011 |
PT prothrombin time, PB peripheral blood
Impact of decreased PT values on survival
As shown in Fig. 1, the median survival of patients with reduced PT values was significantly shorter than in patients with normal PT (19.3 vs. 49.0 months, p = 0.012). Table 3 shows the prognostic power of decreased PT values and established prognostic factors in the study population of CMML patients. As one can see, there was a significant adverse survival impact of all these factors, including leukocytosis > 13 G/L, anemia < 10 g/dL, thrombocytopenia < 100 G/L, and the presence of blast cells in PB. As shown in Table 4, the prognostic significance of PT values was lost in multivariate analysis in the presence of other adverse prognostic factors, indicating the dependence of coagulation abnormalities on parameters of advanced CMML.
Fig. 1.
Kaplan–Meier plots for overall survival of chronic myelomonocytic leukemia patients with and without decreased prothrombin time (PT) values
Table 3.
Univariate analysis of single prognostic parameters in patients with chronic myelomonocytic leukemia
| Factors | Factor present Median OS (months) |
Factor absent Median OS (months) |
P-value (log-rank) |
|---|---|---|---|
| Decreased PT values | 19.3 | 49.0 | 0.012 |
| WBC > 13 × G/L | 23.1 | 49.0 | 0.011 |
| Hb < 10 g/dL | 23.1 | 48.0 | 0.033 |
| PLT < 100 × G/L | 22.7 | 51.6 | 0.001 |
| PB blasts present | 18.8 | 37.3 | 0.002 |
The log-rank test was used to determine if individual parameters were associated with OS
OS overall survival, WBC white blood cell count, Hb hemoglobin, PLT platelet count, PB peripheral blood, PT prothrombin time
Table 4.
Hazard ratios, confidence intervals, and p-values of Cox regression analysis for survival including decreased PT values and established prognostic parameters
| Parameter | Hazard ratio | 95% confidence interval | P-value |
|---|---|---|---|
| PT decreased (< 70%) | 0.720 | 0.380–1.361 | 0.311 |
| WBC ≥ 13 G/L | 1.509 | 0.769–2.961 | 0.231 |
| Hb < 10 g/dL | 1.128 | 0.536–2.375 | 0.751 |
| PLT < 100 × G/L | 2.278 | 1.130–4.593 | 0.021 |
| PB blasts present | 1.735 | 0.900–3.346 | 0.100 |
PT prothrombin time, WBC white blood cell count, Hb hemoglobin, PLT platelet count, PB peripheral blood
Coagulation abnormality in a patient with advanced CMML
In individual patients, disturbances of plasmatic coagulation were analyzed in more detail by the determination of single clotting factors. The analysis of one of these patients, who has already transformed into CMML-related AML, is shown in Table 5. As one can see, liver parameters, including bilirubin, ASAT, ALAT, gamma-GT, and alkaline phosphatase, were increased, whereas cholinesterase was decreased, indicating liver cell damage. Regarding clotting factors, all of them, excluding factor VIII, were decreased, suggesting compromised synthesis of these factors in the liver as opposed to disseminating intravascular coagulation in which all factors, including factor VIII, are typically decreased.
Table 5.
Liver and coagulation parameters in a single patient with leukemia-associated liver failure
| Parameter | Result | Normal values |
|---|---|---|
| ASAT | 56 U/L | < 31 U/L |
| ALAT | 51 U/L | < 34 U/L |
| Gamma-GT | 99 U/L | < 38 U/L |
| Alkaline phosphatase | 236 U/L | < 104 U/L |
| Cholinesterase | 1146 U/L | 4000–12 000 U/L |
| Bilirubin | 1.98 mg/dL | 0.2–1.2 mg/dL |
| LDH | 1309 U/L | 125–243 U/L |
| PT | 44% | 70–130% |
| aPTT | 50.4 s | 23–37 s |
| Fibrinogen | 1.17 g/L | 2.13–3.93 g/L |
| D‑dimer | 1.9 mg/L | < 0.5 mg/L |
| ATIII activity | 20% | 80–130% |
| Factor II activity | 25% | 79–131% |
| Factor V activity | 46% | 75–130% |
| Factor VII activity | 19% | 75–160% |
| Factor X activity | 50% | 70–150% |
| Factor VIII activity | 113% | 60–160% |
| Factor IX activity | 49% | 60–140% |
| Factor XI activity | 34% | 60–140% |
| Factor XII activity | 23% | 60–140% |
| Factor XIII activity | 62% | 70–140% |
PT prothrombin time, aPTT activated partial thromboplastin time
Discussion
Abnormalities of plasmatic coagulation in CMML were described in 1979 in a few patients. In a series of 9 patients, 7 had abnormal coagulation values; in 2 cases, abnormalities were consistent with disseminated intravascular coagulation that correlated with hemorrhagic diathesis [25]. Cells of the human myelomonocytic line RC-2A synthesize tissue factor-like procoagulant and urokinase-type plasminogen activator [26]. Overall, the clinical significance of disturbed plasmatic coagulation abnormalities in patients with CMML is poorly investigated.
In this paper, we show that decreased PT values are an adverse prognostic parameter in CMML. This finding is new and has not been, to the best of our knowledge, reported by others. Interestingly, decreased PT values were not associated with significant bleeding tendency, including the incidence of major bleeding. It has to be noted, however, that the number of CMML patients with information regarding bleeding complications was low. By correlating PT values with laboratory parameters, we found higher leukocyte counts, a higher proportion of circulating blast cells, and lower platelet counts in CMML patients with decreased PT. Moreover, we found that the prognostic significance of PT values was lost in the presence of established prognostic factors such as leukocytosis, anemia, thrombocytopenia, and circulating blasts in multivariate analysis. Altogether, these results suggest that blood coagulation abnormalities in CMML patients may not be an independent prognostic factor but may be associated with more advanced disease. Since blood coagulation parameters are synthesized in the liver, one could speculate that blood coagulation abnormalities may be due to infiltration of the liver by CMML cells. Indeed, it has been shown that in a subgroup of patients with CMML, hepatomegaly can be demonstrated [27]. Moreover, we have seen a correlation of decreased PT values with increased liver parameters, and could demonstrate in single patients with detailed analysis of coagulation factors a reduction of coagulation factors excluding factor VIII, which is a characteristic pattern for impaired liver synthesis. There were 2 patients with subnormal fibrinogen levels and normal PT values. Although not analyzed, one can speculate that in these patients, increased production of urokinase-type plasminogen activator may have contributed to this finding, as was proposed in a previous study [26].
We are aware of the limitations of our study. For example, most of the information used in this study was derived from retrospective real-world data that were not collected systematically or prospectively. Thus, not every parameter was available in all patients. In addition, data from patient records were obtained over many years and from many different centers. Moreover, the patients included in this study represented a relatively heterogenous population regarding the blast cell counts. However, real-world data have recently been recognized as an important way to get insights into routine management and the natural history of rare diseases [28]. CMML is a rare disease, and adequate patient numbers for a systematic and prospective study are not easy to collect within a limited timeframe. Moreover, the ABCMML provides information derived from molecular as well as from functional studies, and therefore allows a more comprehensive view and deeper insight into the complex pathophysiology of this hematologic malignancy [22].
Acknowledgments
Funding
This study was supported by the Gesellschaft zur Erforschung der Biologie und Therapie von Tumorkrankheiten—ABCMML-112015.
Author Contribution
C. Weinfurtner performed administration of the data, collected clinical information, and performed statistical analysis; K. Geissler and C. Weinfurtner wrote the manuscript; K. Geissler directed the research and collected, analyzed, and interpreted the data. Both authors have read and agreed to the published version of the manuscript.
Funding
Open access funding provided by Sigmund Freud Privatuniversität Wien.
Conflict of interest
C. Weinfurtner and K. Geissler declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189–199. doi: 10.1111/j.1365-2141.1982.tb08475.x. [DOI] [PubMed] [Google Scholar]
- 2.Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–2302. doi: 10.1182/blood-2002-04-1199. [DOI] [PubMed] [Google Scholar]
- 3.Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. doi: 10.1182/blood-2009-03-209262. [DOI] [PubMed] [Google Scholar]
- 4.Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544. [DOI] [PubMed] [Google Scholar]
- 5.Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99(3):840–849. doi: 10.1182/blood.V99.3.840. [DOI] [PubMed] [Google Scholar]
- 6.Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504–1510. doi: 10.1038/leu.2013.88. [DOI] [PubMed] [Google Scholar]
- 7.Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31(19):2428–2436. doi: 10.1200/JCO.2012.47.3314. [DOI] [PubMed] [Google Scholar]
- 8.Elena C, Gallì A, Such E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408–1417. doi: 10.1182/blood-2016-05-714030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Machherndl-Spandl S, Jäger E, Barna A, et al. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. Eur J Haematol. 2021;107(2):265–274. doi: 10.1111/ejh.13647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fenaux P, Beuscart R, Lai JL, et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol. 1988;6(9):1417–1424. doi: 10.1200/JCO.1988.6.9.1417. [DOI] [PubMed] [Google Scholar]
- 11.Germing U, Strupp C, Aivado M, et al. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002;100(2):731–732. doi: 10.1182/blood-2002-01-0330. [DOI] [PubMed] [Google Scholar]
- 12.Storniolo AM, Moloney WC, Rosenthal DS, et al. Chronic myelomonocytic leukemia. Leukemia. 1990;4(11):766–770. [PubMed] [Google Scholar]
- 13.Schuler E, Schroeder M, Neukirchen J, et al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res. 2014;38(12):1413–1419. doi: 10.1016/j.leukres.2014.09.003. [DOI] [PubMed] [Google Scholar]
- 14.Tefferi A, Hoagland HC, Therneau TM, et al. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc. 1989;64(10):1246–1254. doi: 10.1016/S0025-6196(12)61287-7. [DOI] [PubMed] [Google Scholar]
- 15.Worsley A, Oscier DG, Stevens J, et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68(1):17–21. doi: 10.1111/j.1365-2141.1988.tb04173.x. [DOI] [PubMed] [Google Scholar]
- 16.Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375–383. doi: 10.3324/haematol.2010.030957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005–3015. doi: 10.1182/blood-2012-08-452938. [DOI] [PubMed] [Google Scholar]
- 18.Wassie EA, Itzykson R, Lasho TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111–1115. doi: 10.1002/ajh.23846. [DOI] [PubMed] [Google Scholar]
- 19.Itzykson R, Fenaux P, Bowen D, et al. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European leukemianet. Hemasphere. 2018;2(6):e150. doi: 10.1097/HS9.0000000000000150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206–2212. doi: 10.1038/leu.2014.125. [DOI] [PubMed] [Google Scholar]
- 21.Padron E, Garcia-Manero G, Patnaik MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5(7):e333. doi: 10.1038/bcj.2015.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Geissler K, Jäger E, Barna A, et al. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): a representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019;131(17–18):410–418. doi: 10.1007/s00508-019-1526-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441–1450. doi: 10.1038/leu.2013.100. [DOI] [PubMed] [Google Scholar]
- 24.Foucar K, Hsi ED, Wang SA, et al. Concordance among hematopathologists in classifying blasts plus promonocytes: a bone marrow pathology group study. Int J Lab Hem. 2020;42(4):418–422. doi: 10.1111/ijlh.13212. [DOI] [PubMed] [Google Scholar]
- 25.Gingrich RD, Burns CP. Disseminated coagulopathy in chronic myelomonocytic leukemia. Cancer. 1979;44(6):2249–2253. doi: 10.1002/1097-0142(197912)44:6<2249::AID-CNCR2820440637>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
- 26.Karhumäki E, Saravo L, Helin H. Cells of the human myelomonocytic line RC-2A synthesize tissue factor-like procoagulant and urokinase-type plasminogen activator. J Leukoc Biol. 1987;42(1):36–42. doi: 10.1002/jlb.42.1.36. [DOI] [PubMed] [Google Scholar]
- 27.Fenaux P, Jouet JP, Zandecki M, et al. Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol. 1987;65(1):101–106. doi: 10.1111/j.1365-2141.1987.tb06142.x. [DOI] [PubMed] [Google Scholar]
- 28.Khozin S, Blumenthal GM, Pazdur R. Real-world Data for Clinical Evidence Generation in Oncology. Jnci: J Natl Cancer Inst. 2017 doi: 10.1093/jnci/djx187. [DOI] [PubMed] [Google Scholar]